Ezogabine (retigabine)

Carl E. Stafstrom; Seden Grippon; Peter Kirkpatrick

doi:10.1038/nrd3561

Ezogabine (retigabine)

Carl E. Stafstrom, Seden Grippon, Peter Kirkpatrick

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

Original language	English (US)
Pages (from-to)	729-730
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	10
Issue number	10
DOIs	https://doi.org/10.1038/nrd3561
State	Published - Oct 2011
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1038/nrd3561

Cite this

@article{01433719011f4602b2f363b10fb2dbf4,

title = "Ezogabine (retigabine)",

abstract = "Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).",

author = "Stafstrom, {Carl E.} and Seden Grippon and Peter Kirkpatrick",

year = "2011",

month = oct,

doi = "10.1038/nrd3561",

language = "English (US)",

volume = "10",

pages = "729--730",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Ezogabine (retigabine)

AU - Stafstrom, Carl E.

AU - Grippon, Seden

AU - Kirkpatrick, Peter

PY - 2011/10

Y1 - 2011/10

N2 - Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

AB - Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

UR - http://www.scopus.com/inward/record.url?scp=80053558884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053558884&partnerID=8YFLogxK

U2 - 10.1038/nrd3561

DO - 10.1038/nrd3561

M3 - Article

C2 - 21959281

AN - SCOPUS:80053558884

SN - 1474-1776

VL - 10

SP - 729

EP - 730

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 10

ER -

Ezogabine (retigabine)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this